Get the Stockscreener App
2.29
2.14%
-0.05
Nautilus Biotechnology Inc stock is traded at $2.29, with a volume of 22,061.
It is down -2.14% in the last 24 hours and down -17.33% over the past month.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. It has built a prototype of a single-molecule instrument, Proteomic Analysis System.
See More
Previous Close:
$2.34
Open:
$2.36
24h Volume:
22,061
Relative Volume:
0.27
Market Cap:
$285.03M
Revenue:
-
Net Income/Loss:
$-63.68M
P/E Ratio:
-4.8723
EPS:
-0.47
Net Cash Flow:
$-54.15M
1W Performance:
-6.91%
1M Performance:
-17.33%
6M Performance:
-17.33%
1Y Performance:
-15.19%
1-Day Range:
$2.28
$2.39
1-Week Range:
$2.21
$2.49
52-Week Range:
$2.19
$3.4547
Nautilus Biotechnology Inc Stock (NAUT) Company Profile
Name
Nautilus Biotechnology Inc
Sector
Industry
Phone
206-333-2001
Address
2701 EASTLAKE AVE EAST, SEATTLE
Compare NAUT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| NAUT | 2.30 | 285.03M | 0 | -63.68M | -54.15M | -0.47 |
| VRTX | 446.52 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.51 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.70 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 250.25 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.17 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Nautilus Biotechnology Inc Stock (NAUT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-22 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-02-21 | Initiated | Cowen | Outperform |
| Aug-04-21 | Initiated | Goldman | Neutral |
| Jul-13-21 | Initiated | Jefferies | Buy |
Nautilus Biotechnology Inc Stock (NAUT) Latest News
Nautilus Biotechnology Reports Q3 2024 Financial Results - MSN
3 US Penny Stocks With Market Caps Up To $400M - Simply Wall St
Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy for Radiology and Biomedical Imaging Research's Distinguished Investigator Award - Quantisnow
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q3 2024 Earnings Call Transcript - Insider Monkey
Nautilus Biotechnology Co-founder and Chief Scientist Parag - GlobeNewswire
Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy for Radiology and Biomedical Imaging Research’s Distinguished Investigator Award - Morningstar
Nautilus Biotechnology Faces ESG Challenges Amid Regulatory Pressure and Investor Scrutiny - TipRanks
Glass House Brands to Host Third Quarter 2024 Conference Call on November 13, 2024 - The Manila Times
Nautilus Biotechnology to Participate in the Inaugural Guggenheim Healthcare Conference - GlobeNewswire
SG Americas Securities LLC Takes Position in Cardlytics, Inc. (NASDAQ:CDLX) - Defense World
Nautilus Biotechnology Reports Third Quarter 2024 Financial Results - GlobeNewswire
Nautilus Biotechnology reports Q3 EPS (13c), consensus (16c) - TipRanks
Nautilus Biotechnology (NAUT) Scheduled to Post Quarterly Earnings on Tuesday - MarketBeat
Renaissance Technologies LLC Decreases Stock Holdings in Immix Biopharma, Inc. (NASDAQ:IMMX) - Defense World
Renaissance Technologies LLC Acquires 9,459 Shares of Toro Corp. (NASDAQ:TORO) - Defense World
Renaissance Technologies LLC Has $358,000 Stock Holdings in Standard Lithium Ltd. (NYSE:SLI) - Defense World
Renaissance Technologies LLC Cuts Stock Holdings in OPKO Health, Inc. (NASDAQ:OPK) - Defense World
Nautilus Biotechnology Inc. - Scrip
We Think Nautilus Biotechnology (NASDAQ:NAUT) Can Afford To Drive Business Growth - Yahoo Finance
Nautilus Biotechnology to Announce Third Quarter 2024 Financial Results on October 29, 2024 - The Manila Times
nautilus biotechnology, inc. Earnings dates - RTTNews
Clearline Capital LP Lowers Stake in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
Tech Moves: GE healthcare exec joins startup; Nautilus taps new CMO; WRF investor steps down - MSN
Insider Selling: Nautilus Biotechnology, Inc. (NASDAQ:NAUT) VP Sells 47,031 Shares of Stock - Defense World
Nautilus Biotechnology senior VP sells over $134k in company stock - Investing.com
Caxton Associates LP Acquires 131,589 Shares of Entegris, Inc. (NASDAQ:ENTG) - Defense World
2 Kite vets fly over to Kyverna Therapeutics—Chutes & Ladders - Fierce Biotech
Nautilus Biotechnology senior VP sells shares worth over $99k - Investing.com India
Nautilus Biotechnology senior VP sells shares worth over $99k By Investing.com - Investing.com Canada
New CEOs at Nura, IMU - BioCentury
Nautilus Biotechnology Appoints Mass Spectrometry Leader Ken Suzuki as Chief Marketing Officer | Daily - Daily Guardian Canada
Nautilus Biotechnology Appoints Mass Spectrometry Leader Ken Suzuki as Chief Marketing Officer - GlobeNewswire
Nautilus Biotechnology, Inc.'s (NASDAQ:NAUT) Top Key Executive Parag Mallick is the most upbeat insider, and their holdings increased by 11% last week - Simply Wall St
Nautilus Biotechnology (NASDAQ:NAUT) Stock Price Down 0.8% - MarketBeat
Who Is Jeff Bezos: History, Background, Achievements, and Net Worth - Investing.com
Dr. Parag Mallick, PhDCo-Founder, Nautilus BiotechnologyUnlocking The Complexity Of The Proteome For A New Era Of Scientific Discovery - Audacy
Nautilus Biotechnology Insider Ups Holding During Year - Yahoo Finance
XPeng Inc. (NYSE:XPEV) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Vanguard Group Inc. Acquires 29,604 Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
Nautilus Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - StockTitan
Nautilus Biotechnology (NASDAQ:NAUT) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q2 2024 Earnings Call Transcript - Insider Monkey
Nautilus Biotechnology, Inc. (NAUT) Q2 2024 Earnings Call Transcript - Seeking Alpha
NAUT Stock Earnings: Nautilus Biotechnology Beats EPS for Q2 2024 - InvestorPlace
Nautilus Down on Releasing Q2 Numbers - Baystreet.ca
Nautilus Biotechnology Reports Second Quarter 2024 Financial Results - GlobeNewswire
Nautilus Biotechnology Inc Stock (NAUT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):